price month
 close
could drive upsid increas tp
bottom line share trade sinc tuesday see
move investor get comfort stori
approach end compani dark period fill extens patent
expir hamper compani abil grow come
june loe lyrica last major one forese futur
combin new product stori compris multipl
underappreci pipelin asset catalyst beyond lead
us continu recommend stock updat model follow
result lead us increas target price reiter
outperform rate
despit neg tanezumab data growth driver
look promis recent neg long-term phase oa data
tanezumab setback pipelin still see tafamidi rare
diseas vaccin underappreci driver pipelin upsid
beyond also look growth key market product
eliqui xtandi xeljanz well ibranc assum adjuv data
read posit next year addit encourag strong
ex-u growth upjohn divis off-pat legaci brand especi
china look upjohn growth continu lyrica loe
wash
multipl pipelin catalyst line come month oral jak
phase atop dermat data may septemb dmd
initi data six patient june tafamidi pdufa juli
valuat risk slightli adjust ep estim
target price
blend dcf rel valuat dcf base
wacc termin growth rel valuat
base new ep main risk view
commercial/clin trial setback surpris develop
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price may rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
pfizer inc biopharmaceut compani engag
discoveri develop manufactur sale medicin
blue sky valuat base greater sale
ibranc prevnar xtandi eliqui compar current base case
assumpt also model higher oper margin
base case assumpt blue sky valuat base dcf
driven wacc termin valu
grey sky valuat base lower sale ibranc
prevnar xtandi eliqui compar current base case
assumpt also model lower oper margin
base case assumpt grey sky valuat base dcf
driven wacc termin valu
 close
follow
opportun speak member team follow
confer call gain addit clariti dynam
 current expect regard rebat
plan number scenario
compani readi whether rebat happen
 price bigger scenario
less focu part less rev part
 robust growth upjohn sustain
growth china probabl strongest china favor
expect loe lyrica impact growth expect low
singl digit growth beyond
 much currenc play role gross margin
strong op margin em china spend
short term loe lyrica hurt gm op margin wash
 regard difficil vaccin patient popul
prevent vaccin would seek age-bas recommend mayb
enrol complet data expect
believ differ sanofi program give compani fight chanc
program work
way administ may may success vs sanofi
sanofi went dose regimen went
also studi shot tri demonstr immunogen one
vaccin prime immun system remind vaccin system
 function data june dmd gene therapi
probabl function data
data patient treat
 xeljanz destock quarter
jak high rebat class
higher rebat quarter unfavor channel mix contribut
differ volum growth revenu growth
 seen impact high dose xeljanz uc dvt/pe
look rx trend continu grow doesnt appear impact
 what market share ibranc us
ibranc volum flat quarter price help littl bit
class class breast cancer market
fewer sell day week worth vs key reason
sale europ lower
 inflectra sequenti sale quarter
 declin due custom buy pattern
increas payer rebat moder volum growth continu
achiev open system off-set price eros
outsid highli competit environ neg impact
volum price also fewer sell day impact
sale sequenti
us million unless otherwis state
us million unless otherwis state
us million unless otherwis state
tax charl martineau pm univers toronto
us million unless otherwis state
allianc revenu direct famili franchis allianc intern allianc inotuzumab ozogamicin charl martineau pm univers toronto
us million unless otherwis state
mnb difficil vaccin phase phase phase biosimilar remicad inflamm charl martineau pm univers toronto
us million unless otherwis state
us million unless otherwis state
profit research total incom provis incom non-controlling averag per analysisgross margin per charl martineau pm univers toronto
compani mention price
vamil divan md certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
